

**REMARKS:**

Claims 2 and 15-17 are in the case and presented for consideration.

Claim 2 has been amended to highlight the distinction between the presently claimed invention and the cited reference.

**Rejection Under 35 U.S.C. §102(b)**

Claims 2 and 15-17 were rejected under 35 U.S.C. §102(b) as being anticipated by U.S. Patent No. 3,817,981 to Kampe et al. ("Kampe et al.").

Claim 2 has been amended to clarify that it neither contains any of the compounds disclosed in Kampe et al., nor any positional isomers thereof.

Therefore, because Kampe et al. fails to disclose or suggest elements of currently amended independent claim 2, from which claims 15-17 depend, it does not anticipate any of the claims currently in the case.

## **Conclusion**

Accordingly, Applicants believe that all the claims are now in condition for allowance and favorable action is respectfully requested. Should there be any issues that have not been addressed to the Examiner's satisfaction, Applicants invite the Examiner to contact the undersigned attorney.

If any fees other than those submitted herewith are due in connection with this response, please charge such fees to Deposit Account No. 14-1431.

Respectfully submitted,  
/NADER A. ABADIR/  
Nader A. Abadir  
Reg. No. 52,537  
Attorney for Applicants  
(845) 359-7700

Dated: December 18, 2009

**NOTARO & MICHALOS P.C.**  
100 Dutch Hill Road, Suite 110  
Orangeburg, New York 10962-2100

**Customer No. 21706**

R:\PATAMD\J507-005\2009-09-18OA\J507-005-AMD2.wpd